[{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Ivy Brain Tumor Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"VT-01","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivace Therapeutics \/ Ivy Brain Tumor Center","highestDevelopmentStatusID":"4","companyTruncated":"Vivace Therapeutics \/ Ivy Brain Tumor Center"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"YAP-TEAD transcription activity","graph1":"Oncology","graph2":"Preclinical","graph3":"Vivace Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Vivace Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"4","companyTruncated":"Vivace Therapeutics \/ Boxer Capital"},{"orgOrder":0,"company":"Vivace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VT3989","moa":"TEAD palmitoylation","graph1":"Oncology","graph2":"Phase I","graph3":"Vivace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vivace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivace Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vivace Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vietnam Medi-Pharm Expo
                          Not Confirmed
                          Vietnam Medi-Pharm Expo
                          Not Confirmed

                          Details : VT3989 works by inhibiting the palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. It has shown its activity as a monotherapy against tumors that rely upon dysfunction of the hippo pathway.

                          Product Name : VT3989

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 15, 2023

                          Lead Product(s) : VT3989

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Vietnam Medi-Pharm Expo
                          Not Confirmed
                          Vietnam Medi-Pharm Expo
                          Not Confirmed

                          Details : Vivace Therapeutics’s compounds inhibit palmitoylation of members of the transcriptional enhanced associate domain (TEAD) protein family.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 16, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Boxer Capital

                          Deal Size : $30.0 million

                          Deal Type : Series C Financing

                          blank

                          03

                          Vietnam Medi-Pharm Expo
                          Not Confirmed
                          Vietnam Medi-Pharm Expo
                          Not Confirmed

                          Details : The Ivy Brain Tumor Center, which employs a bold, early-phase clinical trials strategy, will evaluate Vivace’s novel development compound, VT-01, as an experimental therapy in two aggressive forms of brain cancer – glioblastoma and meningioma.

                          Product Name : VT-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 26, 2020

                          Lead Product(s) : VT-01

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Ivy Brain Tumor Center

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank